Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-07-26 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON THE COMPLETION OF THE REPURCHASE OF A SHARES OF THE COMPANY
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of the repurchase of A shares by Pharmaron Beijing Co., Ltd. It details the number of shares repurchased, the prices, the total funds used, and the impact on the company's shareholding structure. It also mentions the cancellation of the repurchased shares and subsequent amendments to the company's registered capital and Articles of Association. The document is not a financial report, earnings release, or management discussion but rather a formal announcement about a share repurchase transaction. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2024-07-26 English
INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR INTERIM RESULTS OF 2024
Earnings Release Classification · 95% confidence The document is an announcement titled 'INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR INTERIM RESULTS OF 2024' by Pharmaron Beijing Co., Ltd. It provides estimated financial results for the interim period January 1, 2024 to June 30, 2024, including revenue and net profit estimates, with explanations of non-recurring gains and losses. The announcement explicitly states that the financial data is preliminary, unaudited, and that the formal interim report will be published later. The document is about estimated interim results, not the actual interim report itself. It is a regulatory announcement providing inside information on expected interim financial performance, consistent with a Capital/Financing Update or Earnings Release. However, since it is an estimate and not the official earnings release, and it is an announcement of estimated results rather than the full report, the best fitting category is Earnings Release (ER), which covers initial announcements of quarterly/periodical financial results (key highlights only). The document is over 10,000 characters and contains substantive financial data estimates, supporting classification as ER rather than a brief announcement or RPA. Therefore, the filing type is ER with high confidence. H1 2024
2024-07-21 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-07-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, convertibles, other agreements to issue shares, and repurchase of shares. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, providing detailed share capital and shareholding movements for the month. The document is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory filing related to share capital and securities movements, fitting the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance document under exchange rules.
2024-07-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It includes detailed tables of share repurchases, dates, prices, and confirmations of compliance with listing rules. The document references specific listing rules from the Hong Kong Stock Exchange and Shenzhen Stock Exchange. It is a regulatory disclosure about share repurchases and changes in capital structure rather than a financial report or earnings release. The content fits the description of a Transaction in Own Shares (POS) filing, which reports the company's buyback or sale of its own shares. The document length and detail confirm it is not a brief announcement but a full disclosure report on share transactions.
2024-07-04 English
REPURCHASE AND WITHDRAWAL OF LISTING OF US$300 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026
Delisting Announcement Classification · 95% confidence The document is an announcement from Pharmaron Beijing Co., Ltd. regarding the repurchase and cancellation of all outstanding zero coupon convertible bonds and the subsequent withdrawal of the listing of these bonds from the Hong Kong Stock Exchange. The text references previous announcements and details the completion of the repurchase and the expected effective date of the withdrawal of listing. The document is short (2462 characters) and serves as an official notice about a capital market transaction and listing status change, not a full financial report or detailed financial data. It fits the category of a Delisting Announcement (DLST) because it announces the withdrawal of the listing of the bonds from the exchange.
2024-07-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.